RBC Capital analyst, Randall Stanicky,reiterated his Outperform rating on shares of INSYS Therapeutics (NASDAQ: INSY) after a CEO succession plan ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE